In this Majority Report clip, Alexandria Ocasio-Cortez does her thing. We need your help to keep providing free videos! Support the Majority Report's video content by going to
"Rep. Alexandria Ocasio-Cortez, D-N.Y., didn't hold back Thursday in questioning the chief executive of the company that makes Truvada about the high cost of the drug used to prevent HIV with pre-exposure prophylaxis, or PrEP.
"The list price is almost $2,000 in the United States. Why is it $8 in Australia?" Ocasio-Cortez asked the CEO of Gilead Sciences, Daniel O'Day, after noting the company made $3 billion in revenue off the once-a-day pill in 2018.
O'Day responded that "Truvada still has patent protection in the United States, and in the rest of the world it is generic." He noted that, as announced last week, the drug is set to be generically available in the U.S. in September 2020.
“There’s no reason this should be $2,000 a month," Ocasio-Cortez, who has pushed for the hearing before the House Committee on Oversight and Reform. "People are dying because of it, and there’s no enforceable reason for it.”*
Read more here:
Watch the Majority Report live M–F at 12 p.m. EST at youtube.com/samseder or listen via daily podcast at
Download our FREE app:
SUPPORT the show by becoming a member:
LIKE us on Facebook:
FOLLOW us on Twitter:
SUBSCRIBE to us on YouTube:
0 Comments